Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (39,690,815)	$ (20,652,565)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of contingent consideration liability	(120,000)	13,640,000
Impairment loss on construction-in-progress	8,070,000
Stock-based compensation expense	2,703,180	545,431
Depreciation and amortization	149,388	146,045
Unrealized losses (gains) on foreign currency exchange	10,108	(18,851)
Changes in operating assets and liabilities:
Accounts receivable	(93,672)	(160,920)
Prepaid expenses and other current assets	(7,155,593)	(343,337)
Accounts payable	808,899	176,985
Accrued expenses and other liabilities	(4,052,095)	26,761
Tax refund receivable	874,812	(4,877,851)
Net cash used in operating activities	(38,495,788)	(11,518,302)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sales and maturities of short-term investments	63,712,000	24,900,000
Purchases of short-term investments	(7,424,005)	(12,118,563)
Purchases of property and equipment, net	(11,900,198)	(40,601)
Cash paid for internally developed patents	(145,546)	(79,336)
Net cash provided by investing activities	44,242,251	12,661,500
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of deferred offering costs	(118,522)	(179,743)
Proceeds from exercises of warrants		31,310,137
Proceeds from issuance of common stock in at the market offerings, net	52,356,204	22,780,729
Proceeds from issuance of notes payable		632,000
Proceeds from issuance of common stock from Employee Stock Purchase Plan	106,001	56,739
Proceeds from exercises of stock options	94,429	36,175
Net cash provided by financing activities	52,438,112	54,636,037
Net increase in cash and cash equivalents and restricted cash	58,184,575	55,779,235
Cash, cash equivalents and restricted cash at beginning of period	115,951,981	8,996,860
Cash, cash equivalents and restricted cash at end of period	$ 174,136,556	$ 64,776,095